<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Principles of Neoplasia | Fundamentals of Pathology</title>
    
<!-- Preconnect for performance -->
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>

<!-- Google Fonts -->
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">

<!-- Main Stylesheet -->
<link rel="stylesheet" href="../styles/main.css">

<!-- MathJax Configuration -->
<script>
MathJax = {
    tex: {
        inlineMath: [['$', '$'], ['\\(', '\\)']],
        displayMath: [['$$', '$$'], ['\\[', '\\]']],
        processEscapes: true,
        processEnvironments: true,
        tags: 'ams'
    },
    svg: { fontCache: 'global' },
    options: {
        skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
    }
};
</script>
<script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
<!-- Reading Progress Bar -->
<div class="reading-progress-container" aria-hidden="true">
    <div class="reading-progress-bar" id="reading-progress"></div>
</div>

<!-- Theme Toggle -->
<button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode" title="Toggle dark mode">
    <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
    <span class="theme-toggle-icon dark-icon">üåô</span>
</button>

<div class="page-wrapper">
    <!-- Floating Mini-TOC -->
    <aside class="floating-toc" id="floating-toc" aria-label="On this page">
        <div class="floating-toc-header">
            <span class="floating-toc-icon">üìë</span>
            <span>On this page</span>
        </div>
        <nav class="floating-toc-nav">
            <ul class="floating-toc-list">
                <!-- Populated by JS -->
            </ul>
        </nav>
    </aside>

    <div class="container">
        <article class="document-article" role="main" id="main-content">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document navigation">
                <div class="nav-container">
                    <a href="../index.html" class="nav-button nav-button--toc" aria-label="Table of Contents">
                        <span class="nav-icon">üìö</span>
                        <span class="nav-text">Contents</span>
                    </a>
                    
                    <a href="chapter-02-inflammation.html" class="nav-button nav-button--prev" aria-label="Previous section">
                        <span class="nav-icon">‚Üê</span>
                        <span class="nav-text">Previous</span>
                    </a>
                    
                    <div class="document-progress">
                        <div class="progress-indicator">
                            <span class="progress-current">3</span>
                            <span class="progress-separator">/</span>
                            <span class="progress-total">19</span>
                        </div>
                        <div class="progress-bar-container" aria-hidden="true">
                            <div class="progress-bar-fill" style="width: 15%;"></div>
                        </div>
                        <span class="progress-label">Principles of Neoplasia</span>
                    </div>
                    
                    <a href="chapter-04-hemostasis.html" class="nav-button nav-button--next" aria-label="Next section">
                        <span class="nav-text">Next</span>
                        <span class="nav-icon">‚Üí</span>
                    </a>
                </div>
            </nav>

            <!-- Breadcrumb -->
            <nav class="breadcrumb" aria-label="Breadcrumb">
                <ol class="breadcrumb-list">
                    <li class="breadcrumb-item"><a href="../index.html">Home</a></li>
                    <li class="breadcrumb-item active" aria-current="page">Chapter 3</li>
                </ol>
            </nav>

            <!-- Document Header -->
            <header class="document-header">
                <div class="header-badge">
                    <span class="badge-icon">ü¶Ä</span>
                    <span class="badge-text">Oncology</span>
                </div>
                <h1 class="document-title">Principles of Neoplasia</h1>
                <div class="title-meta">
                    <span class="meta-item">
                        <span class="meta-icon">üìÑ</span>
                        <span>Chapter 3</span>
                    </span>
                </div>
            </header>

            <!-- Main Content Area -->
            <div class="content-wrapper">
                
                <!-- Neoplasia Section -->
                <section id="neoplasia-intro" class="content-section">
                    <h2 class="section-title">Neoplasia</h2>
                    
                    <div class="content-card">
                        <h3 id="basic-principles">I. Basic Principles</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">Neoplasia is new tissue growth that is unregulated, irreversible, and monoclonal; these features distinguish it from hyperplasia and repair.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">Monoclonal means that the neoplastic cells are derived from a single mother cell.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">
                                    <p>Clonality was historically determined by glucose-6-phosphate dehydrogenase (G6PD) enzyme isoforms.</p>
                                    <ol>
                                        <li>Multiple isoforms (e.g., $G_6PD_A, G_6PD_B, \text{ and } G_6PD_C$) exist; only one isoform is inherited from each parent.</li>
                                        <li>In females, one isoform is randomly inactivated in each cell by lyonization (G6PD is present on the X chromosome).</li>
                                        <li>Normal ratio of active isoforms in cells of any tissue is 1:1 (e.g., $50\%$ of cells have $G_6PD_A$, and $50\%$ of cells have $G_6PD_B$).</li>
                                        <li>1:1 ratio is maintained in hyperplasia, which is polyclonal (cells are derived from multiple cells).</li>
                                        <li>Only one isoform is present in neoplasia, which is monoclonal.</li>
                                        <li>Clonality can also be determined by androgen receptor isoforms, which are also present on the X chromosome.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">D</span>
                                <div class="list-content">
                                    <p>Clonality of B lymphocytes is determined by immunoglobulin (Ig) light chain phenotype.</p>
                                    <ol>
                                        <li>Ig is comprised of heavy and light chains.</li>
                                        <li>Each B cell expresses light chain that is either kappa or lambda.</li>
                                        <li>Normal kappa to lambda light chain ratio is 3:1.</li>
                                        <li>This ratio is maintained in hyperplasia, which is polyclonal.</li>
                                        <li>Ratio increases to $>6:1$ or is inverted (e.g., kappa to lambda ratio $= 1:3$) in lymphoma, which is monoclonal.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">E</span>
                                <div class="list-content">
                                    <p>Neoplastic tumors are benign or malignant.</p>
                                    <ol>
                                        <li>Benign tumors remain localized and do not metastasize.</li>
                                        <li>Malignant tumors (cancer) invade locally and have the potential to metastasize.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">F</span>
                                <div class="list-content">Tumor nomenclature is based on lineage of differentiation (type of tissue produced) and whether the tumor is benign or malignant (Table 3.1).</div>
                            </li>
                        </ul>
                    </div>

                    <!-- Table 3.1 -->
                    <div class="table-wrapper">
                        <div class="table-header">
                            <span class="table-icon">üìä</span>
                            <span class="table-caption">Table 3.1: Examples of Tumor Nomenclature</span>
                        </div>
                        <div class="table-container">
                            <table class="content-table">
                                <thead>
                                    <tr>
                                        <th>LINEAGE OF DIFFERENTIATION</th>
                                        <th>BENIGN</th>
                                        <th>MALIGNANT (CANCER)</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Epithelium</td>
                                        <td>Adenoma<br>Papilloma</td>
                                        <td>Adenocarcinoma<br>Papillary carcinoma</td>
                                    </tr>
                                    <tr>
                                        <td>Mesenchyme</td>
                                        <td>Lipoma</td>
                                        <td>Liposarcoma</td>
                                    </tr>
                                    <tr>
                                        <td>Lymphocyte</td>
                                        <td>(Does not exist)</td>
                                        <td>Lymphoma/Leukemia</td>
                                    </tr>
                                    <tr>
                                        <td>Melanocyte</td>
                                        <td>Nevus (mole)</td>
                                        <td>Melanoma</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>

                    <div class="content-card">
                        <h3 id="epidemiology">II. Epidemiology</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Cancer is the 2nd leading cause of death in both adults and children.</p>
                                    <ol>
                                        <li>The leading causes of death in adults are (1) cardiovascular disease, (2) cancer, and (3) chronic respiratory disease.</li>
                                        <li>The leading causes of death in children are (1) accidents, (2) cancer, and (3) congenital defects.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">The most common cancers by incidence in adults are (1) breast/prostate, (2) lung, and (3) colorectal.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">The most common causes of cancer mortality in adults are (1) lung, (2) breast/prostate, and (3) colorectal.</div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="screening">III. Role of Screening</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">Cancer begins as a single mutated cell.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">Approximately 30 divisions occur before the earliest clinical symptoms arise.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">
                                    <p>Each division (doubling time) results in increased mutations.</p>
                                    <ol>
                                        <li>Cancers that do not produce symptoms until late in disease will have undergone additional divisions and, hence, additional mutations.</li>
                                        <li>Cancers that are detected late tend to have a poor prognosis.</li>
                                        <li>Screening seeks to catch dysplasia (precancerous change) before it becomes carcinoma or carcinoma before clinical symptoms arise; efficacy of screening, however, requires a decrease in cancer-specific mortality.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">D</span>
                                <div class="list-content">
                                    <p>Common screening methods include</p>
                                    <ol>
                                        <li>Pap smear‚Äîdetects cervical dysplasia (CIN) before it becomes carcinoma</li>
                                        <li>Mammography‚Äîdetects in situ breast cancer (e.g., DCIS) before it invades or invasive carcinoma before it becomes clinically palpable</li>
                                        <li>Prostate specific antigen (PSA) and digital rectal exam‚Äîdetects prostate carcinoma before it spreads</li>
                                        <li>Hemoccult test (for occult blood in stool) and colonoscopy‚Äîdetect colonic adenoma before it becomes colonic carcinoma or carcinoma before it spreads</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>
                </section>

                <!-- Carcinogenesis Section -->
                <section id="carcinogenesis" class="content-section">
                    <h2 class="section-title">Carcinogenesis</h2>

                    <div class="content-card">
                        <h3 id="carcinogenesis-principles">I. Basic Principles</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Cancer formation is initiated by damage to DNA of stem cells. The damage overcomes DNA repair mechanisms, but is not lethal.</p>
                                    <ol>
                                        <li>Carcinogens are agents that damage DNA, increasing the risk for cancer. Important carcinogens include chemicals, oncogenic viruses, and radiation (Table 3.2).</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>DNA mutations eventually disrupt key regulatory systems, allowing for tumor promotion (growth) and progression (spread).</p>
                                    <ol>
                                        <li>Disrupted systems include proto-oncogenes, tumor suppressor genes, and regulators of apoptosis.</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>

                    <!-- Table 3.2 -->
                    <div class="table-wrapper">
                        <div class="table-header">
                            <span class="table-icon">üß™</span>
                            <span class="table-caption">Table 3.2: Important Carcinogens and Associated Cancers</span>
                        </div>
                        <div class="table-container">
                            <table class="content-table">
                                <thead>
                                    <tr>
                                        <th>CARCINOGENIC AGENT</th>
                                        <th>ASSOCIATED CANCER</th>
                                        <th>COMMENTS</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td colspan="3"><strong>CHEMICALS</strong></td>
                                    </tr>
                                    <tr>
                                        <td>Aflatoxins</td>
                                        <td>Hepatocellular carcinoma</td>
                                        <td>Derived from Aspergillus, which can contaminate stored rice and grains</td>
                                    </tr>
                                    <tr>
                                        <td>Alkylating agents</td>
                                        <td>Leukemia/lymphoma</td>
                                        <td>Side effect of chemotherapy</td>
                                    </tr>
                                    <tr>
                                        <td>Alcohol</td>
                                        <td>Squamous cell carcinoma of oropharynx and upper esophagus, and hepatocellular carcinoma</td>
                                        <td></td>
                                    </tr>
                                    <tr>
                                        <td>Arsenic</td>
                                        <td>Squamous cell carcinoma of skin, lung cancer, and angiosarcoma of liver</td>
                                        <td>Arsenic is present in cigarette smoke.</td>
                                    </tr>
                                    <tr>
                                        <td>Asbestos</td>
                                        <td>Lung carcinoma and mesothelioma</td>
                                        <td>Exposure to asbestos is more likely to lead to lung cancer than mesothelioma.</td>
                                    </tr>
                                    <tr>
                                        <td>Cigarette smoke</td>
                                        <td>Carcinoma of oropharynx, esophagus, lung, kidney, bladder, and pancreas</td>
                                        <td>Most common carcinogen worldwide; polycyclic hydrocarbons are particularly carcinogenic.</td>
                                    </tr>
                                    <tr>
                                        <td>Nitrosamines</td>
                                        <td>Stomach carcinoma</td>
                                        <td>Found in smoked foods; responsible for high rate of stomach carcinoma in Japan</td>
                                    </tr>
                                    <tr>
                                        <td>Naphthylamine</td>
                                        <td>Urothelial carcinoma of bladder</td>
                                        <td>Derived from cigarette smoke</td>
                                    </tr>
                                    <tr>
                                        <td>Vinyl chloride</td>
                                        <td>Angiosarcoma of liver</td>
                                        <td>Occupational exposure; used to make polyvinyl chloride (PVC) for use in pipes</td>
                                    </tr>
                                    <tr>
                                        <td>Nickel, chromium, beryllium, or silica</td>
                                        <td>Lung carcinoma</td>
                                        <td>Occupational exposure</td>
                                    </tr>
                                    <tr>
                                        <td colspan="3"><strong>ONCOGENIC VIRUSES</strong></td>
                                    </tr>
                                    <tr>
                                        <td>EBV</td>
                                        <td>Nasopharyngeal carcinoma, Burkitt lymphoma, and CNS lymphoma in AIDS</td>
                                        <td></td>
                                    </tr>
                                    <tr>
                                        <td>HHV-8</td>
                                        <td>Kaposi sarcoma</td>
                                        <td></td>
                                    </tr>
                                    <tr>
                                        <td>HBV and HCV</td>
                                        <td>Hepatocellular carcinoma</td>
                                        <td></td>
                                    </tr>
                                    <tr>
                                        <td>HTLV-1</td>
                                        <td>Adult T-cell leukemia/lymphoma</td>
                                        <td></td>
                                    </tr>
                                    <tr>
                                        <td>High-risk HPV (e.g., subtypes 16, 18, 31, 33)</td>
                                        <td>Squamous cell carcinoma of vulva, vagina, anus, and cervix; adenocarcinoma of cervix</td>
                                        <td></td>
                                    </tr>
                                    <tr>
                                        <td colspan="3"><strong>RADIATION</strong></td>
                                    </tr>
                                    <tr>
                                        <td>Ionizing (nuclear reactor accidents and radiotherapy)</td>
                                        <td>AML, CML, and papillary carcinoma of the thyroid</td>
                                        <td>Generates hydroxyl free radicals</td>
                                    </tr>
                                    <tr>
                                        <td>Nonionizing (UVB sunlight is most common source)</td>
                                        <td>Basal cell carcinoma, squamous cell carcinoma, and melanoma of skin</td>
                                        <td>Results in formation of pyrimidine dimers in DNA, which are normally excised by restriction endonuclease</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>

                    <div class="content-card">
                        <h3 id="oncogenes">II. Oncogenes</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">Proto-oncogenes are essential for cell growth and differentiation; mutations of proto-oncogenes form oncogenes that lead to unregulated cellular growth.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>Categories of oncogenes include growth factors, growth factor receptors, signal transducers, nuclear regulators, and cell cycle regulators (Table 3.3).</p>
                                    <ol>
                                        <li>Growth factors induce cellular growth (e.g., PDGFB in astrocytoma).</li>
                                        <li>Growth factor receptors mediate signals from growth factors (e.g., ERBB2 [HER2/neu] in breast cancer).</li>
                                        <li>Signal transducers relay receptor activation to the nucleus (e.g., ras).
                                            <ol type="i">
                                                <li>Ras is associated with growth factor receptors in an inactive GDP-bound state.</li>
                                                <li>Receptor binding causes GDP to be replaced with GTP, activating ras.</li>
                                                <li>Activated ras sends growth signals to the nucleus.</li>
                                                <li>Ras inactivates itself by cleaving GTP to GDP; this is augmented by GTPase activating protein.</li>
                                                <li>Mutated ras inhibits the activity of GTPase activating protein. This prolongs the activated state of ras, resulting in increased growth signals.</li>
                                            </ol>
                                        </li>
                                        <li>Cell cycle regulators mediate progression through the cell cycle (e.g., cyclin and cyclin-dependent kinase).
                                            <ol type="i">
                                                <li>Cyclins and cyclin-dependent kinases (CDKs) form a complex which phosphorylates proteins that drive the cell through the cell cycle.</li>
                                                <li>For example, the cyclinD/CDK4 complex phosphorylates the retinoblastoma protein, which promotes progression through the $G_1/S$ checkpoint.</li>
                                            </ol>
                                        </li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>

                    <!-- Table 3.3 -->
                    <div class="table-wrapper">
                        <div class="table-header">
                            <span class="table-icon">üß¨</span>
                            <span class="table-caption">Table 3.3: Important Oncogenes and Associated Tumors</span>
                        </div>
                        <div class="table-container">
                            <table class="content-table">
                                <thead>
                                    <tr>
                                        <th>FUNCTION</th>
                                        <th>MECHANISM</th>
                                        <th>ASSOCIATED TUMOR</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td colspan="3"><strong>GROWTH FACTOR</strong></td>
                                    </tr>
                                    <tr>
                                        <td>PDGFB</td>
                                        <td>Overexpression, autocrine loop</td>
                                        <td>Astrocytoma</td>
                                    </tr>
                                    <tr>
                                        <td colspan="3"><strong>GROWTH FACTOR RECEPTORS</strong></td>
                                    </tr>
                                    <tr>
                                        <td>ERBB2 [HER2/neu]</td>
                                        <td>Amplification</td>
                                        <td>Subset of breast carcinomas</td>
                                    </tr>
                                    <tr>
                                        <td>RET</td>
                                        <td>Point mutation</td>
                                        <td>MEN 2A, MEN 2B and sporadic medullary carcinoma of thyroid</td>
                                    </tr>
                                    <tr>
                                        <td>KIT</td>
                                        <td>Point mutation</td>
                                        <td>Gastrointestinal stromal tumor</td>
                                    </tr>
                                    <tr>
                                        <td colspan="3"><strong>SIGNAL TRANSDUCERS</strong></td>
                                    </tr>
                                    <tr>
                                        <td>RAS gene family</td>
                                        <td>Point mutation</td>
                                        <td>Carcinomas, melanoma, and lymphoma</td>
                                    </tr>
                                    <tr>
                                        <td>ABL</td>
                                        <td>t(9;22) with BCR</td>
                                        <td>CML and some types of ALL</td>
                                    </tr>
                                    <tr>
                                        <td colspan="3"><strong>NUCLEAR REGULATORS</strong></td>
                                    </tr>
                                    <tr>
                                        <td>c-MYC</td>
                                        <td>t(8;14) involving IgH</td>
                                        <td>Burkitt lymphoma</td>
                                    </tr>
                                    <tr>
                                        <td>N-MYC</td>
                                        <td>Amplification</td>
                                        <td>Neuroblastoma</td>
                                    </tr>
                                    <tr>
                                        <td>L-MYC</td>
                                        <td>Amplification</td>
                                        <td>Lung carcinoma (small cell)</td>
                                    </tr>
                                    <tr>
                                        <td colspan="3"><strong>CELL CYCLE REGULATORS</strong></td>
                                    </tr>
                                    <tr>
                                        <td>CCND1 (cyclin D1)</td>
                                        <td>t(11;14) involving IgH</td>
                                        <td>Mantle cell lymphoma</td>
                                    </tr>
                                    <tr>
                                        <td>CDK4</td>
                                        <td>Amplification</td>
                                        <td>Melanoma</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>

                    <div class="content-card">
                        <h3 id="tumor-suppressors">III. Tumor Suppressor Genes</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">Regulate cell growth and, hence, decrease ("suppress") the risk of tumor formation; p53 and Rb (retinoblastoma) are classic examples.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>p53 regulates progression of the cell cycle from $G_1$ to S phase.</p>
                                    <ol>
                                        <li>In response to DNA damage, p53 slows the cell cycle and upregulates DNA repair enzymes.</li>
                                        <li>If DNA repair is not possible, p53 induces apoptosis.
                                            <ol type="i">
                                                <li>p53 upregulates BAX, which disrupts Bcl2.</li>
                                                <li>Cytochrome $c$ leaks from the mitochondria activating apoptosis.</li>
                                            </ol>
                                        </li>
                                        <li>Both copies of the p53 gene must be knocked out for tumor formation (Knudson two-hit hypothesis).
                                            <ol type="i">
                                                <li>Loss is seen in $>50\%$ of cancers.</li>
                                                <li>Germline mutation results in Li-Fraumeni syndrome (2nd hit is somatic), characterized by the propensity to develop multiple types of carcinomas and sarcomas.</li>
                                            </ol>
                                        </li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">
                                    <p>Rb also regulates progression from $G_1$ to S phase.</p>
                                    <ol>
                                        <li>Rb "holds" the E2F transcription factor, which is necessary for transition to the S phase.</li>
                                        <li>E2F is released when RB is phosphorylated by the cyclinD/cyclin-dependent kinase 4 (CDK4) complex.</li>
                                        <li>Rb mutation results in constitutively free E2F, allowing progression through the cell cycle and uncontrolled growth of cells.</li>
                                        <li>Both copies of Rb gene must be knocked out for tumor formation (Knudson two-hit hypothesis).
                                            <ol type="i">
                                                <li>Sporadic mutation (both hits are somatic) is characterized by unilateral retinoblastoma (Fig. 3.1).</li>
                                                <li>Germline mutation results in familial retinoblastoma (2nd hit is somatic), characterized by bilateral retinoblastoma and osteosarcoma.</li>
                                            </ol>
                                        </li>
                                    </ol>
                                </div>
                            </li>
                        </ul>

                        <!-- Fig 3.1 -->
                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../../../../../assets/images/image-20251213-75b0b6cf.jpeg" 
                                     alt="Retinoblastoma showing white mass in eye" 
                                     class="figure-image"
                                     loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 3.1 Retinoblastoma. (Courtesy of Jerome Taxy, MD)</figcaption>
                        </figure>
                    </div>

                    <div class="content-card">
                        <h3 id="apoptosis-regulators">IV. Regulators of Apoptosis</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Prevent apoptosis in normal cells, but promote apoptosis in mutated cells whose DNA cannot be repaired (e.g., Bcl2)</p>
                                    <ol>
                                        <li>Bcl2 normally stabilizes the mitochondrial membrane, blocking release of cytochrome $c$.</li>
                                        <li>Disruption of Bcl2 allows cytochrome $c$ to leave the mitochondria and activate apoptosis.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>Bcl2 is overexpressed in follicular lymphoma.</p>
                                    <ol>
                                        <li>t(14;18) moves Bcl2 (chromosome 18) to the Ig heavy chain locus (chromosome 14), resulting in increased Bcl2.</li>
                                        <li>Mitochondrial membrane is further stabilized, prohibiting apoptosis.</li>
                                        <li>B cells that would normally undergo apoptosis during somatic hypermutation in the lymph node germinal center accumulate, leading to lymphoma.</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="other-features">V. Other Important Features of Tumor Development</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Telomerase is necessary for cell immortality.</p>
                                    <ol>
                                        <li>Normally, telomeres shorten with serial cell divisions, eventually resulting in cellular senescence.</li>
                                        <li>Cancers often have upregulated telomerase, which preserves telomeres.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>Angiogenesis (production of new blood vessels) is necessary for tumor survival and growth.</p>
                                    <ol>
                                        <li>FGF and VEGF (angiogenic factors) are commonly produced by tumor cells.</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">
                                    <p>Avoiding immune surveillance is necessary for tumor survival.</p>
                                    <ol>
                                        <li>Mutations often result in production of abnormal proteins, which are expressed on MHC class I.</li>
                                        <li>$CD8^+$ T cells detect and destroy such mutated cells.</li>
                                        <li>Tumor cells can evade immune surveillance by downregulating expression of MHC class I.</li>
                                        <li>Immunodeficiency (both primary and secondary) increases risk for cancer.</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>
                </section>

                <!-- Tumor Progression Section -->
                <section id="tumor-progression" class="content-section">
                    <h2 class="section-title">Tumor Progression</h2>

                    <div class="content-card">
                        <h3 id="invasion-spread">I. Tumor Invasion and Spread</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Accumulation of mutations eventually results in tumor invasion and spread.</p>
                                    <ol>
                                        <li>Epithelial tumor cells are normally attached to one another by cellular adhesion molecules (e.g., E-cadherin).</li>
                                        <li>Downregulation of E-cadherin leads to dissociation of attached cells.</li>
                                        <li>Cells attach to laminin and destroy basement membrane (collagen type IV) via collagenase.</li>
                                        <li>Cells attach to fibronectin in the extracellular matrix and spread locally.</li>
                                        <li>Entrance into vascular or lymphatic spaces allows for metastasis (distant spread).</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="metastasis-routes">II. Routes of Metastasis</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Lymphatic spread is characteristic of carcinomas.</p>
                                    <ol>
                                        <li>Initial spread is to regional draining lymph nodes (Fig. 3.2).</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>Hematogenous spread is characteristic of sarcomas and some carcinomas.</p>
                                    <ol>
                                        <li>Renal cell carcinoma (often invades renal vein)</li>
                                        <li>Hepatocellular carcinoma (often invades hepatic vein)</li>
                                        <li>Follicular carcinoma of the thyroid</li>
                                        <li>Choriocarcinoma</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">Seeding of body cavities is characteristic of ovarian carcinoma, which often involves the peritoneum ('omental caking', Fig. 3.3).</div>
                            </li>
                        </ul>

                        <div class="figure-grid">
                            <!-- Fig 3.2 -->
                            <figure class="content-figure" data-lightbox="true">
                                <div class="figure-image-wrapper">
                                    <img src="../../../../../assets/images/image-20251213-ee79401d.jpeg" 
                                         alt="Carcinoma invading lymph node" 
                                         class="figure-image"
                                         loading="lazy">
                                    <div class="figure-overlay">
                                        <span class="overlay-icon">üîç</span>
                                        <span class="overlay-text">Click to enlarge</span>
                                    </div>
                                </div>
                                <figcaption class="figure-caption">Fig. 3.2 Carcinoma involving lymph node.</figcaption>
                            </figure>

                            <!-- Fig 3.3 -->
                            <figure class="content-figure" data-lightbox="true">
                                <div class="figure-image-wrapper">
                                    <img src="../../../../../assets/images/image-20251213-05fa4d8c.jpeg" 
                                         alt="Omental caking by carcinoma" 
                                         class="figure-image"
                                         loading="lazy">
                                    <div class="figure-overlay">
                                        <span class="overlay-icon">üîç</span>
                                        <span class="overlay-text">Click to enlarge</span>
                                    </div>
                                </div>
                                <figcaption class="figure-caption">Fig. 3.3 Seeding of the omentum by carcinoma. (Courtesy of Jerome Taxy, MD)</figcaption>
                            </figure>
                        </div>
                    </div>
                </section>

                <!-- Clinical Characteristics Section -->
                <section id="clinical-characteristics" class="content-section">
                    <h2 class="section-title">Clinical Characteristics</h2>

                    <div class="content-card">
                        <h3 id="clinical-features">I. Clinical Features</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">Benign tumors tend to be slow growing, well circumscribed, distinct, and mobile.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">Malignant tumors are usually rapid growing, poorly circumscribed, infiltrative, and fixed to surrounding tissues and local structures.</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">
                                    <p>Biopsy or excision is generally required before a tumor can be classified as benign or malignant with certainty.</p>
                                    <ol>
                                        <li>Some benign tumors can grow in a malignant-like fashion, and some malignant tumors can grow in a benign-like fashion.</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="histologic-features">II. Histologic Features</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Benign tumors are usually well differentiated (Fig. 3.4A). Characteristics include</p>
                                    <ol>
                                        <li>Organized growth</li>
                                        <li>Uniform nuclei</li>
                                        <li>Low nuclear to cytoplasmic ratio</li>
                                        <li>Minimal mitotic activity</li>
                                        <li>Lack of invasion (of basement membrane or local tissue)</li>
                                        <li>No metastatic potential</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">
                                    <p>Malignant tumors are classically poorly differentiated (anaplastic, Fig. 3.4B). Characteristics include</p>
                                    <ol>
                                        <li>Disorganized growth (loss of polarity)</li>
                                        <li>Nuclear pleomorphism and hyperchromasia</li>
                                        <li>High nuclear to cytoplasmic ratio</li>
                                        <li>High mitotic activity with atypical mitosis</li>
                                        <li>Invasion (through basement membrane or into local tissue)</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">Metastatic potential is the hallmark of malignancy‚Äîbenign tumors never metastasize.</div>
                            </li>
                        </ul>

                        <!-- Fig 3.4 -->
                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../../../../../assets/images/image-20251213-1bca74c3.jpeg" 
                                     alt="A. Well differentiated follicular adenoma vs B. Poorly differentiated anaplastic carcinoma" 
                                     class="figure-image"
                                     loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 3.4 Histologic features of neoplasia. A, Well differentiated, follicular adenoma of thyroid. B, Poorly differentiated, anaplastic carcinoma of thyroid.</figcaption>
                        </figure>

                        <li class="list-item">
                            <span class="list-marker">D</span>
                            <div class="list-content">Immunohistochemistry is used to characterize tumors that are difficult to classify on histology (Fig. 3.5, Table 3.4).</div>
                        </li>

                        <!-- Fig 3.5 -->
                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../../../../../assets/images/image-20251213-8e26e390.jpeg" 
                                     alt="Immunohistochemical stain for keratin" 
                                     class="figure-image"
                                     loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 3.5 Immunohistochemical stain for keratin marking epithelial cells (in brown).</figcaption>
                        </figure>
                    </div>

                    <!-- Table 3.4 -->
                    <div class="table-wrapper">
                        <div class="table-header">
                            <span class="table-icon">üî¨</span>
                            <span class="table-caption">Table 3.4: Common Immunohistochemical Stains and Target Cell Types</span>
                        </div>
                        <div class="table-container">
                            <table class="content-table">
                                <thead>
                                    <tr>
                                        <th>IMMUNOHISTOCHEMICAL STAIN</th>
                                        <th>TISSUE TYPE</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td colspan="2"><strong>INTERMEDIATE FILAMENTS</strong></td>
                                    </tr>
                                    <tr>
                                        <td>Keratin</td>
                                        <td>Epithelium</td>
                                    </tr>
                                    <tr>
                                        <td>Vimentin</td>
                                        <td>Mesenchyme</td>
                                    </tr>
                                    <tr>
                                        <td>Desmin</td>
                                        <td>Muscle</td>
                                    </tr>
                                    <tr>
                                        <td>GFAP</td>
                                        <td>Neuroglia</td>
                                    </tr>
                                    <tr>
                                        <td>Neurofilament</td>
                                        <td>Neurons</td>
                                    </tr>
                                    <tr>
                                        <td colspan="2"><strong>OTHERS</strong></td>
                                    </tr>
                                    <tr>
                                        <td>PSA</td>
                                        <td>Prostatic epithelium</td>
                                    </tr>
                                    <tr>
                                        <td>ER</td>
                                        <td>Breast epithelium</td>
                                    </tr>
                                    <tr>
                                        <td>Thyroglobulin</td>
                                        <td>Thyroid follicular cells</td>
                                    </tr>
                                    <tr>
                                        <td>Chromogranin</td>
                                        <td>Neuroendocrine cells (e.g., small cell carcinoma of lung and carcinoid tumors)</td>
                                    </tr>
                                    <tr>
                                        <td>S-100</td>
                                        <td>Melanoma, Schwannoma and Langerhans cell histiocytosis</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>

                    <div class="content-card">
                        <h3 id="tumor-markers">III. Serum Tumor Markers</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">Proteins released by tumor into serum (e.g., PSA)</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">Useful for screening, monitoring response to treatment, and monitoring recurrence</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">Elevated levels require tissue biopsy for diagnosis of carcinoma (e.g., biopsy of prostate with elevated PSA).</div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="grading">IV. Grading of Cancer</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">
                                    <p>Microscopic assessment of differentiation (i.e., how much a cancer resembles the tissue in which it grows); takes into account architectural and nuclear features</p>
                                    <ol>
                                        <li>Well differentiated (low grade)‚Äîresembles normal parent tissue</li>
                                        <li>Poorly differentiated (high grade)‚Äîdoes not resemble parent tissue</li>
                                    </ol>
                                </div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">Important for determining prognosis; well-differentiated cancers have better prognosis than poorly-differentiated cancers.</div>
                            </li>
                        </ul>
                    </div>

                    <div class="content-card">
                        <h3 id="staging">V. Staging of Cancer</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">A</span>
                                <div class="list-content">Assessment of size and spread of a cancer</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">B</span>
                                <div class="list-content">Key prognostic factor; more important than grade</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">C</span>
                                <div class="list-content">Determined after final surgical resection of the tumor</div>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">D</span>
                                <div class="list-content">
                                    <p>Utilizes TNM staging system</p>
                                    <ol>
                                        <li>T‚Äîtumor (size and/or depth of invasion)</li>
                                        <li>N‚Äîspread to regional lymph nodes; second most important prognostic factor</li>
                                        <li>M‚Äîmetastasis; single most important prognostic factor</li>
                                    </ol>
                                </div>
                            </li>
                        </ul>
                    </div>
                </section>

            </div>

            <!-- Bottom Navigation -->
            <nav class="document-nav document-nav--bottom" role="navigation" aria-label="Document navigation">
                <div class="nav-container">
                    <a href="chapter-02-inflammation.html" class="nav-button nav-button--prev nav-button--large">
                        <span class="nav-icon">‚Üê</span>
                        <div class="nav-content">
                            <span class="nav-label">Previous</span>
                            <span class="nav-title">Inflammation, Inflammatory Disorders, and Wound Healing</span>
                        </div>
                    </a>
                    
                    <a href="../index.html" class="nav-button nav-button--toc">
                        <span class="nav-icon">üìö</span>
                        <span class="nav-text">All Topics</span>
                    </a>
                    
                    <a href="chapter-04-hemostasis.html" class="nav-button nav-button--next nav-button--large">
                        <div class="nav-content">
                            <span class="nav-label">Next</span>
                            <span class="nav-title">Hemostasis and Related Disorders</span>
                        </div>
                        <span class="nav-icon">‚Üí</span>
                    </a>
                </div>
            </nav>
        </article>
    </div>
</div>

<!-- Lightbox Modal -->
<div class="lightbox-modal" id="lightbox-modal" role="dialog" aria-modal="true" aria-label="Image viewer" hidden>
    <div class="lightbox-backdrop"></div>
    <div class="lightbox-content">
        <button class="lightbox-close" aria-label="Close image viewer">√ó</button>
        <img class="lightbox-image" src="" alt="">
        <p class="lightbox-caption"></p>
    </div>
</div>

<!-- JavaScript Dependencies -->
<script src="../js/theme.js"></script>
<script src="../js/navigation.js"></script>
<script src="../js/interactions.js"></script>
</body>
</html>
  